Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.
The more abnormalities in intestinal and brain function that IBS sufferers have, the more severe their symptoms of this functional bowel disorder, and the more adversely their everyday life is affected.
The U.S. Food and Drug Administration today approved Benlysta (belimumab) intravenous infusion for treatment of children with systemic lupus erythematosus – often referred to as simply "lupus" – a serious chronic disease that causes inflammation and damage to various body tissues and organs.
A research group at Hiroshima University observed a potential new target for chronic pain treatment. Further research using this receptor could lead to new, more effective drugs to use in pain-relieving treatment for chronic pain.
January 18, 2018, ACROBiosystems officially opened its New Innovation laboratory in the Delaware Innovation Space in Wilmington, Delaware, USA, and held a grand opening ceremony.
The neural 'time windows' in certain small brain areas contribute to the complex cognitive symptoms of autism, new research suggests.
In animal models of a totally crushed peripheral nerve, the damaged axons are broken down, allowing healthy ones to regrow.
It is a common health problem that causes uncommon personal discomfort. Fecal incontinence, or accidental stool leakage, affects some 8 to 10 percent of the 325 million people in the United States. In up to half of patients, there is both fecal and urinary incontinence.
A detailed study of four mouse models of autism challenges the most common assumption about what goes wrong in brain circuits to cause disease symptoms.
New research shows that a simple non-invasive hearing test early in life could predict the diagnosis of autism. The results of this study, titled 'Structural and Functional Aberrations of the Auditory Brainstem in Autism Spectrum Disorder', is published in the latest issue of the The Journal of the American Osteopathic Association (JAOA).
A noninvasive hearing test may assist with early detection and diagnosis of autism spectrum disorders, according to research published in the Journal of the American Osteopathic Association.
Research suggests that celiac disease could be caused by a bacterial enzyme used to manufacture sausages, cheese, bread and other processed foods.
A novel way in which the inflammatory response to pain is regulated has been described in the open-access journal eLife.
The holiday season is a hard one for anyone watching their weight. The sights and smells of food are hard to resist.
The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
Human leukocyte antigen molecules are a group of proteins that help the immune system identify foreign invaders such as viruses and bacteria and which impact a wide variety of clinical outcomes including infection and cancer.
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.
TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.